🧬 CRISPR Therapeutics (CRSP) Stock Holds Steady at 52-Week Low, Promising Future Prospects in Anemia Treatment ⬆️💉

Introduction

CRISPR Therapeutics AG (NASDAQ: CRSP), a leader in gene-editing technologies, closed at $38.94 on October 31, 2023. The stock didn't record any change in price on this date, and stood at its 52-week low of $38.93, far from the 52-week high of $72. The current market capitalization is $3.45 billion. The total volume of shares traded was 2.69 million, which is more than double the average volume of 1.09 million shares.

Technical Analysis

CRISPR's 14-day Relative Strength Index (RSI) stands at 31, indicating that the stock is nearing the oversold territory. The stock's 50-day moving average is $45.65, and the 200-day moving average is $51.37. The negative Moving Average Convergence Divergence (MACD) of -1.66 could signify a bearish trend. The Average True Range (ATR), a measure of volatility, is 5.36.

The nearest support level is $38.74, close to the last closing price, while the resistance level is at $39.11. Maintaining above the support level would be a positive sign for stockholders.

Fundamental Analysis

CRISPR has reported a negative Earnings Per Share (EPS) of -5.3 and a negative Price to Earnings (PE) ratio of -8.19, suggesting that the firm is currently not profitable. The number of outstanding shares is around 79.41 million.

However, it's important to highlight the news that the company's treatment for sickle cell anemia, exa-cel, has been regarded as safe by an FDA advisory committee. This shows promise for future developments and might trigger positive sentiment in the market.

Analyst Recommendations and Target Prices

Analysts have a "Buy" consensus on the stock, with six analysts recommending a "Buy" and two recommending a "Hold". The stock has a low price target of $63, a median target of $140 and a high target of $180. The consensus target is $130.69. The potential upside, as indicated by the Discounted Cash Flow (DCF) analysis, is $46.13.

Outlook

Looking towards the next trading day, November 1, 2023, and the following week, the stock could see some action as investors react to the FDA advisory committee's positive remarks on CRISPR's treatment for sickle cell anemia. If optimism persists, the stock could push towards its resistance level at $39.11.

However, if the broader market conditions worsen due to unexpected changes in Federal Reserve policy, the stock could retreat to its support level at $38.74. Due to the company's fundamental improvement and pending FDA approval, the technical weakness might be short-lived.

Final Evaluation

Despite short-term technical weakness, CRISPR Therapeutics presents promising long-term prospects du [...]

👉 Dive deeper into our analysis and predictions! CLICK HERE NOW